Dong-A St (170900) - Total Liabilities
Based on the latest financial reports, Dong-A St (170900) has total liabilities worth ₩747.62 Billion KRW (≈ $506.65 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 170900 cash generation efficiency to assess how effectively this company generates cash.
Dong-A St - Total Liabilities Trend (2013–2024)
This chart illustrates how Dong-A St's total liabilities have evolved over time, based on quarterly financial data. Check Dong-A St liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Dong-A St Competitors by Total Liabilities
The table below lists competitors of Dong-A St ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Media and Games Invest PLC
ST:M8G
|
Sweden | Skr804.09 Million |
|
Cymechs Inc
KQ:160980
|
Korea | ₩27.33 Billion |
|
First Community Corporation
NASDAQ:FCCO
|
USA | $1.91 Billion |
|
Anora Group Oyj
HE:ANORA
|
Finland | €639.20 Million |
|
OVB Holding AG
XETRA:O4B
|
Germany | €200.87 Million |
|
Polyplex (Thailand) Public Company Limited
BK:PTL
|
Thailand | ฿5.97 Billion |
|
Blue Foundry Bancorp
NASDAQ:BLFY
|
USA | $1.84 Billion |
|
FutureChem Co.Ltd
KQ:220100
|
Korea | ₩19.40 Billion |
Liability Composition Analysis (2013–2024)
This chart breaks down Dong-A St's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Dong-A St (170900) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.53 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Dong-A St's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Dong-A St (2013–2024)
The table below shows the annual total liabilities of Dong-A St from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩682.93 Billion ≈ $462.81 Million |
+17.52% |
| 2023-12-31 | ₩581.11 Billion ≈ $393.81 Million |
+24.27% |
| 2022-12-31 | ₩467.61 Billion ≈ $316.90 Million |
+1.74% |
| 2021-12-31 | ₩459.61 Billion ≈ $311.47 Million |
+35.75% |
| 2020-12-31 | ₩338.57 Billion ≈ $229.44 Million |
-6.71% |
| 2019-12-31 | ₩362.92 Billion ≈ $245.94 Million |
-1.73% |
| 2018-12-31 | ₩369.31 Billion ≈ $250.28 Million |
+15.94% |
| 2017-12-31 | ₩318.53 Billion ≈ $215.86 Million |
-33.28% |
| 2016-12-31 | ₩477.40 Billion ≈ $323.52 Million |
-6.35% |
| 2015-12-31 | ₩509.77 Billion ≈ $345.46 Million |
-14.11% |
| 2014-12-31 | ₩593.52 Billion ≈ $402.22 Million |
+20.55% |
| 2013-12-31 | ₩492.36 Billion ≈ $333.66 Million |
-- |
About Dong-A St
Dong-A ST Co., Ltd. develops, manufactures, and markets pharmaceutical products in South Korea and internationally. It offers various ethical drugs, including Clofazimine cap. For lepromatous leprosy; Closerin Cap for active pulmonary and extra-pulmonary tuberculosis; Eporon inj./PFS for anemia associated with chronic renal failure; Gemcit inj. to treat non-small cell lung, pancreatic, breast, bl… Read more